GZ-793A
Product Specifications
UNSPSC Description
GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an Ki of 0.029 μM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction[1][2][3].
Target Antigen
Monoamine Transporter
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/gz-793a.html
Purity
99.50
Solubility
H2O : 3 mg/mL (ultrasonic;warming)
Smiles
OC[C@H](O)CN1[C@H](CCC[C@H]1CCC2=CC=C(C=C2)OC)CCC3=CC=C(C=C3)OC.Cl
Molecular Weight
464.04
References & Citations
[1]Wilmouth CE, et al. Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats. Pharmacol Biochem Behav. 2013 Nov;112:29-33.|[2]Nickell JR, et al. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. Eur J Pharmacol. 2017 Jan 15;795:143-149.|[3]Nickell JR, et al. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Adv Pharmacol. 2014;69:71-106.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-117883/GZ-793A-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-117883/GZ-793A-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
1356447-90-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items